Top Markets
#1 Black Phoenix Black Phoenix +355.39%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +62.70%
#4 Akedo Akedo +55.10%
#5 OpenEden OpenEden +54.44%
#6 BasedHype BasedHype +27.45%
#7 Avantis Avantis +21.78%
#8 Cryptopia Cryptopia +21.54%
#9 Acurast Acurast +19.36%
#10 Humanity Humanity +17.48%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rank in Stocks #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Share Price
$0.01292666
Last synced: 2025-04-08
Market Cap
$157.54K
Change (1 day)
6.84%
Change (1 year)
0.00%
Country
GB
Trade Synairgen plc (SNG)

Category

Healthcare
Number of shares outstanding for Synairgen plc (SNG)
Number of shares outstanding as of June 2024: 201.38M
According to Synairgen plc latest financial reports and stock price the company's current number of shares outstanding is 201.38M. At the end of December 2022 the company had 201.36M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Synairgen plc (SNG) from 2004 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 201.38M 0.00%
2023 201.38M 0.01%
2022 201.36M 0.46%
2021 200.44M 36.24%
2020 147.12M 33.64%
2019 110.09M 15.56%
2018 95.26M 1.15%
2017 94.18M 2.48%
2016 91.90M 0.64%
2015 91.32M 3.77%
2014 88.00M 16.35%
2013 75.64M 4.37%
2012 72.47M 19.66%
2011 60.56M 0.77%
2010 60.10M 154.94%
2009 23.57M 8.03%
2008 21.82M -9.98%
2007 24.24M 1.94%
2006 23.78M 26.20%
2005 18.84M 85.90%
2004 10.14M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 26.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -69.12%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -100.00%
BE